Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

21. Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer?

Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do venlafaxine and gabapentin control hot flashes in women with a history of breast (...) cancer? View/ Open Date 2012-12 Format Metadata Abstract Venlafaxine reduces hot flashes more than placebo in women with a history of breast cancer; adverse effects include dry mouth and constipation (strength of recommendation [SOR]: B, randomized clinical trials [RCTs] with heterogeneous outcomes). Gabapentin also reduces hot flashes more than placebo (SOR: B, a single RCT); adverse effects include dizziness and somnolence (SOR: C, standard reference). After having tried both medications, women

Clinical Inquiries2014

22. Gabapentin

Gabapentin USE OF GABAPENTIN IN PREGNANCY 0344 892 0909 USE OF GABAPENTIN IN PREGNANCY (Date of issue: November 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Gabapentin is an antiepileptic drug indicated as monotherapy (...) or adjunctive therapy in the treatment of partial seizures with or without secondary generalisation, and for the treatment of peripheral neuropathic pain. The available data concerning gabapentin exposure in pregnancy consist of relatively small prospective cohort studies (n=8) and ten case reports/series. Most data relates to gabapentin use in pregnancy for the treatment of maternal epilepsy. A few case reports/series describe use of gabapentin in the treatment of neuropathic pain or hyperemesis gravidarum

UK Teratology Information Service2014

23. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014

Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Environmental Scans; issue 45. 2014 Authors' conclusions The survey of Canada's publicly funded drug plans, colleges of physicians and surgeons, and colleges of pharmacists shows that jurisdictions have established multiple avenues to address the issue

Health Technology Assessment (HTA) Database.2014

24. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines

Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) CADTH. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Indirect evidence suggests similar short-term pain relief with gabapentin compared with pregabalin, tricyclic antidepressants and serotonin norepinephrine reuptake inhibitors in patients with painful diabetic neuropathy, postherpetic neuralgia and fibromyalgia. There is lower quality

Health Technology Assessment (HTA) Database.2014

25. Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial

Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial 24190578 2014 01 07 2014 03 10 2017 02 20 2168-6114 174 1 2014 Jan JAMA internal medicine JAMA Intern Med Gabapentin treatment for alcohol dependence: a randomized clinical trial. 70-7 10.1001/jamainternmed.2013.11950 Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics. To determine if gabapentin, a widely prescribed generic calcium channel/γ-aminobutyric acid-modulating medication (...) , increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner. A 12-week, double-blind, placebo-controlled, randomized dose-ranging trial of 150 men and women older than 18 years with current alcohol dependence, conducted from 2004 through 2010 at a single-site, outpatient clinical research facility adjoining a general medical hospital. Oral gabapentin (dosages of 0 [placebo], 900 mg, or 1800 mg/d) and concomitant

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

26. Intrathecal gabapentin to treat chronic intractable noncancer pain

Intrathecal gabapentin to treat chronic intractable noncancer pain 23835590 2013 08 22 2013 11 04 2013 08 22 1528-1175 119 3 2013 Sep Anesthesiology Anesthesiology Intrathecal gabapentin to treat chronic intractable noncancer pain. 675-86 10.1097/ALN.0b013e3182a10fbf Oral gabapentin is approved as an anticonvulsant medication and to treat postherpetic neuralgia. Its nonopioid properties and presumed spinal site of analgesic action made the study on intrathecal gabapentin attractive to establish (...) the minimum effective dose for a later, pivotal trial. The authors examined the safety and efficacy of intrathecal gabapentin in a randomized, blinded, placebo-controlled, multicenter trial in a heterogeneous cohort of candidates with chronic pain for intrathecal drug therapy. Patients (N = 170) were randomized to receive continuous intrathecal gabapentin (0 [placebo], 1, 6, or 30 mg/day) during 22 days of blinded treatment after implantation of a permanent drug delivery system. The highest dose, 30 mg

EvidenceUpdates2013

27. A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial

A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial 23011560 2012 11 23 2013 01 29 2013 11 21 1526-7598 115 6 2012 Dec Anesthesia and analgesia Anesth. Analg. A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial. 1336-42 10.1213/ANE.0b013e31826ac3b9 A single preoperative dose (...) of 600 mg gabapentin, combined with multimodal analgesia, has previously been shown to reduce postcesarean pain and improve maternal satisfaction but was associated with increased maternal sedation. We hypothesized that a lower dose of gabapentin may be effective with less sedation. We conducted a doubleblind, randomized, placebo-controlled study. Women undergoing elective cesarean delivery were randomized into 3 groups to receive 300 or 600 mg oral gabapentin, or placebo, 1 hour before surgery

EvidenceUpdates2012

28. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial.

Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. 22951084 2012 11 05 2013 01 01 2015 06 16 1474-547X 380 9853 2012 Nov 03 Lancet (London, England) Lancet Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. 1583-9 10.1016/S0140-6736(12)60776-4 S0140-6736(12)60776-4 Refractory chronic cough causes substantial symptoms and quality-of-life impairment. Similarities between central reflex sensitisation (...) in refractory chronic cough and neuropathic pain suggest that neuromodulators such as gabapentin might be effective for refractory chronic cough. We established the efficacy of gabapentin in patients with refractory chronic cough. This randomised, double-blind, placebo-controlled trial was undertaken at an outpatient clinic in Australia. Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable

Lancet2012

29. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Make a difference with dentistry's premier charitable organization Take (...) website Evidence Education About * Associated Topics Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has

ADA Center for Evidence-Based Dentistry2011

30. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Take advantage of endorsed, discounted business products Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Make (...) health website Evidence Education About * Associated Topics Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests

ADA Center for Evidence-Based Dentistry2011

31. WITHDRAWN: Gabapentin for acute and chronic pain.

WITHDRAWN: Gabapentin for acute and chronic pain. BACKGROUND: February 2009: The authors are aware of unpublished trial data for Gabapentin which could affect the results of this review. This information together with that from trials published since 2005, will be considered when this review is updated in 2009.Anticonvulsant drugs have been used in the management of pain since the 1960s. The clinical impression is that they are useful for chronic neuropathic pain, especially when the pain (...) is lancinating or burning. OBJECTIVES: To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice. SEARCH STRATEGY: Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966 to Nov 2004), EMBASE (1994 to Nov 2004), SIGLE (1980 to Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2004). Additional studies were identified from the reference list

Cochrane2011

32. Cochrane systematic review: Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term

Cochrane systematic review: Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation

Evidence-Based Nursing (Requires free registration)2011

33. Horizant (gabapentin enacarbil) Extended-Release Tablets

Horizant (gabapentin enacarbil) Extended-Release Tablets Drug Approval Package: Horizant (gabapentin enacarbil) NDA #022399 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Horizant (gabapentin enacarbil) Extended-Release Tablets Company: GlaxoSmithKline Application No.: 022399 Approval Date: 4/06/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2011

34. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate Article Text

Evidence-Based Mental Health2010

35. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, Vakfari A, Kouvelas D CRD summary The authors concluded that pregabalin, at a dose of 450mg daily, was most likely to be effective (...) in treating patients with fibromyalgia, but adverse events were not negligible. Further evidence was necessary to clarify these conclusions. Given the unclear quality of included trials, the authors' cautious conclusion and recommendations for further research seem reasonable. Authors' objectives To evaluate the efficacy and safety/tolerability of gabapentin and pregabalin for treating patients with fibromyalgia. Searching PubMed, EMBASE, PsycINFO, Web of Science, CINAHL, and Cochrane Central Register

DARE.2010

36. Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use

Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions There is a paucity of primary studies comparing the potential for misuse of gabapentin capsules and tablets. There is evidence from case reports that gabapentin capsules may be subject to misuse in certain populations, particularly those

Health Technology Assessment (HTA) Database.2010

37. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

NHS Economic Evaluation Database.2010

38. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials

Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Hauser W, Bernardy K, Uceyler N, Sommer C CRD summary The authors concluded that there was strong evidence that gabapentin and pregabalin could reduce (...) pain, improve sleep and improve health related quality of life for patients with fibromyalgia syndrome. This was a generally well-conducted review. However, limited studies (number and quality), restricted generalisability and prevalent side effects indicate the authors' conclusion should be treated with extreme caution. Authors' objectives To assess the efficacy of gabapentin and pregabalin in the treatment of fibromyalgia syndrome. Searching MEDLINE, PsycINFO, Scopus and The Cochrane Library were

DARE.2009

39. Gabapentin for pain: New evidence from hidden data

Gabapentin for pain: New evidence from hidden data [75] Gabapentin for pain: New evidence from hidden data | Therapeutics Initiative Independent Healthcare Evidence > > [75] Gabapentin for pain: New evidence from hidden data Background Gabapentin (Neurontin) was licensed in Canada in 1993 for adjunctive treatment of epilepsy. In 1998 two double blind randomized controlled trials (DBRCT) suggested mild analgesic effects of gabapentin in painful diabetic peripheral neuropathy (PDPN) and post (...) -herpetic neuralgia (PHN) . Subsequently, unapproved use of gabapentin exploded for pain, migraine, and even as a “mood stabilizer”. (Jan-Feb 2000) reviewed gabapentin for pain. It noted that gabapentin is eliminated by kidney filtration (half-life 6 hours with normal renal function) and that it reduced pain by a mean of 1-2 points on a pain score of 0-10, over 2 weeks, NNT=4 for “moderate or marked” benefit. The Letter concluded: “Gabapentin benefits at best a minority of patients with painful diabetic

Therapeutics Letter2009

40. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Quilici S, Chancellor J, Lothgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B CRD summary This review concluded that duloxetine was comparable (...) in efficacy and tolerability to gabapentin and pregabalin for treatment of diabetic peripheral neuropathic pain. The cautious conclusions of this generally well-conducted review appear reliable, but were based on an indirect comparison of a small number of studies. Authors' objectives To evaluate the efficacy and tolerability of drugs for diabetic peripheral neuropathic pain (DPNP) and to perform indirect comparisons of duloxetine with pregabalin, gabapentin and amitriptyline. Searching PubMed, EMBASE

DARE.2009